PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHAS
Previous Symbol
CUSIPN/A
Phone610-981-6500
Debt
Debt-to-Equity RatioN/A
Current Ratio3.25
Quick Ratio3.25
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees18
Outstanding Shares24,500,000
Market Cap$100.20 million
OptionableNot Optionable
PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions
What is PhaseBio Pharmaceuticals' stock symbol?
PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."
How were PhaseBio Pharmaceuticals' earnings last quarter?
PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) released its earnings results on Thursday, November, 29th. The company reported ($10.45) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $10.23. The firm earned $0.41 million during the quarter. View PhaseBio Pharmaceuticals' Earnings History.
When is PhaseBio Pharmaceuticals' next earnings date?
What price target have analysts set for PHAS?
4 equities research analysts have issued 1-year target prices for PhaseBio Pharmaceuticals' shares. Their forecasts range from $14.00 to $18.00. On average, they expect PhaseBio Pharmaceuticals' share price to reach $16.6667 in the next year. This suggests a possible upside of 323.0% from the stock's current price. View Analyst Price Targets for PhaseBio Pharmaceuticals.
What is the consensus analysts' recommendation for PhaseBio Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PhaseBio Pharmaceuticals.
Has PhaseBio Pharmaceuticals been receiving favorable news coverage?
Press coverage about PHAS stock has been trending very positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. PhaseBio Pharmaceuticals earned a daily sentiment score of 3.6 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of PhaseBio Pharmaceuticals' key competitors?
Some companies that are related to PhaseBio Pharmaceuticals include Corbus Pharmaceuticals (CRBP), ArQule (ARQL), Tyme Technologies (TYME), Progenics Pharmaceuticals (PGNX), Kalvista Pharmaceuticals (KALV), Insys Therapeutics (INSY), ZEALAND PHARMA/S (ZEAL), MediciNova (MNOV), Evolus (EOLS), Clementia Pharmaceuticals (CMTA), American Brivision (Holding) (ABVC), resTORbio (TORC), Aclaris Therapeutics (ACRS), OptiNose (OPTN) and Verastem (VSTM).
Who are PhaseBio Pharmaceuticals' key executives?
PhaseBio Pharmaceuticals' management team includes the folowing people:
- Mr. Jonathan P. Mow, CEO & Director (Age 53)
- Mr. John P. Sharp, Chief Financial Officer (Age 53)
- Dr. John S. Lee, Chief Medical Officer (Age 50)
- Mr. Clay Bernardin Thorp, Chairman (Age 50)
- Mr. Michael B. York, VP of Corp. Devel. & Commercial Strategy (Age 53)
When did PhaseBio Pharmaceuticals IPO?
(PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.
When does the company's lock-up period expire?
PhaseBio Pharmaceuticals' lock-up period expires on Tuesday, April 16th. PhaseBio Pharmaceuticals had issued 9,200,000 shares in its IPO on October 18th. The total size of the offering was $46,000,000 based on an initial share price of $5.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
How do I buy shares of PhaseBio Pharmaceuticals?
Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PhaseBio Pharmaceuticals' stock price today?
One share of PHAS stock can currently be purchased for approximately $3.94.
How big of a company is PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals has a market capitalization of $100.20 million. PhaseBio Pharmaceuticals employs 18 workers across the globe.
What is PhaseBio Pharmaceuticals' official website?
How can I contact PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]
MarketBeat Community Rating for PhaseBio Pharmaceuticals (NASDAQ PHAS)
MarketBeat's community ratings are surveys of what our community members think about PhaseBio Pharmaceuticals and other stocks. Vote "Outperform" if you believe PHAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PHAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
